Strides Pharma Science Limited — Board Meeting, 30-01-2025: Outcome of Board Meeting

The Board has announced the approved unaudited financial results for the quarter and nine months, ending December 31, 2024. The review reflects significant changes due to the approved demerger of the CDMO and Soft Gelatin Business, with financial implications outlined in the accompanying notes. Notably, the amalgamation with Strides Alathur Private Limited was also accounted for as if it occurred at the beginning of the preceding period. This meeting was crucial for aligning the Company’s strategies moving forward while ensuring compliance with relevant accounting standards.